© 2022 MJH Life Sciences and Urology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
Expert panelists review the evolving roles of PSMA-targeted PET imaging and conventional imaging in patients with prostate cancer.
November 7th 2022
Expert panelists review risk stratification strategies for patients with prostate cancer and summarize the evolving use of conventional versus newer imaging modalities for diagnosis, treatment selection, and monitoring of these patients.
A focused discussion on prostate-specific membrane antigen (PSMA) as a target for imaging and treatment for patients with prostate cancer.
November 14th 2022
Panelists consider how they have incorporated some newer imaging modalities, including PSMA-PET, into their clinical practice, and discuss the terminology that urologists and radiologists have recently used to describe these modalities.
Radiologist Gary Ulaner, MD, PhD, FACNM provides a comprehensive discussion on the FDA-approved PSMA radiotracer options that are available for use as part of PSMA-PET imaging.
November 21st 2022
Urologist Ashley Ross, MD, PhD leads a discussion of the benefits and limitations of PSMA-PET in patients with prostate cancer, as compared to older imaging modalities.
Citing recent guidelines recommendations, urologists share how they approach sequencing of conventional and PSMA-PET imaging for patients with prostate cancer, and discuss how use of each modality might affect subsequent patient management and treatment decisions.